Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Capital Expenditures: 2016-2024

Historic Capital Expenditures for Dianthus Therapeutics (DNTH) over the last 9 years, with Dec 2024 value amounting to $105,000.

  • Dianthus Therapeutics' Capital Expenditures fell 80.00% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $106,000, marking a year-over-year increase of 26.19%. This contributed to the annual value of $105,000 for FY2024, which is 4.55% down from last year.
  • According to the latest figures from FY2024, Dianthus Therapeutics' Capital Expenditures is $105,000, which was down 4.55% from $110,000 recorded in FY2023.
  • Dianthus Therapeutics' Capital Expenditures' 5-year high stood at $1.3 million during FY2021, with a 5-year trough of $105,000 in FY2024.
  • Moreover, its 3-year median value for Capital Expenditures was $110,000 (2023), whereas its average is $118,000.
  • In the last 5 years, Dianthus Therapeutics' Capital Expenditures soared by 216.00% in 2021 and then tumbled by 89.00% in 2022.
  • Over the past 5 years, Dianthus Therapeutics' Capital Expenditures (Yearly) stood at $400,000 in 2020, then surged by 216.00% to $1.3 million in 2021, then slumped by 89.00% to $139,000 in 2022, then decreased by 20.86% to $110,000 in 2023, then fell by 4.55% to $105,000 in 2024.